Intravenous methylprednisolone pulse therapy in ankylosing spondylitis

Author(s): Ejstrup L, Peters ND


For several years the medical treatment of active ankylosing spondylitis (AS) has been NSAID because gold, penicillamine, antimalarials and steroids have been without efficacy. In 1981, Mintz et al reported that methylprednisolone pulse therapy (MPPT) had an excellent effect in patients with AS. Seven patients with active AS and insufficient efficacy of NSAID for three months were treated with one gram methylprednisolone daily given intravenously for three successive days. Mobility and pain were recorded before, during, and after treatment. Significant pain relief and improvement of mobility of the spine for at least six weeks were clearly demonstrated (p less than 0.05). Finger to floor distance and chin manubrium distance improved significantly for at least six months (p less than 0.05). We conclude that intravenous MPPT is a useful treatment in patients with active AS when NSAID is insufficient.

Similar Articles

Intravenous pulsed steroids in rheumatoid arthritis: a comparative dose study

Author(s): Iglehart IW 3rd, Sutton JD, Bender JC, Shaw RA, Ziminski CM, et al.

Pulse methylprednisolone in SLE

Author(s): Kimberly RP

Evaluation of diagnostic criteria for ankylosing spondylitis

Author(s): van der Linden S, Valkenburg HA, Cats A

Holter monitoring in ankylosing spondylitis patients during methylprednisolone pulse therapy

Author(s): Nasswetter G, PiƱeiro DJ, Garcia Morteo OM, Maldonado Cocco JA, Barreira JC, et al.